New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)
The current advancements in the treatment of multiple myeloma (MM) involve the use of various therapeutic agents, including immunomodulatory drugs (IMIDs), proteasome inhibitors (PIs), histone deacetylase (HDAC) inhibitors, and monoclonal antibodies (MoAbs). IMIDs such as thalidomide, lenalidomide, and pomalidomide modulate the immune response and inhibit tumor growth. PIs like bortezomib, carfilzomib, and ixazomib block protein degradation and inhibit the NF-kB pathway. MoAbs such as elotuzumab and daratumumab target specific antigens on MM cells and enhance the immune response. HDAC inhibitors like panobinostat and vorinostat modulate gene expression. Combination therapies involving these agents are being explored to improve outcomes. Personalized medicine and targeted therapies are crucial in tailoring treatment strategies for MM patients. Ongoing research and clinical trials aim to transform MM into a chronic disease with improved survival and quality of life for patients.
Important Points:
- The abstract discusses the treatment of relapsed multiple myeloma (MM) patients using pomalidomide, an immunomodulatory drug (IMID).
- Clinical trials have shown that pomalidomide, in combination with low-dose dexamethasone, has significant efficacy in relapsed MM patients.
- The maximum tolerated dose (MTD) of pomalidomide was found to be 2.5 mg.
- The overall response rate (ORR) with pomalidomide was 51%.
- The progression-free survival (PFS) with pomalidomide was 10.4 months.
- The safety profile of pomalidomide is similar to that of lenalidomide, with hematological side effects being the main source of toxicity.
- Pomalidomide has also shown some activity in genomically defined high-risk relapsed MM patients.
- Bendamustine, another novel alkylator, has been approved in Europe for the treatment of newly diagnosed MM patients who are not candidates for autologous stem cell transplantation.
- Bendamustine has shown benefit in terms of time to progression when compared to melphalan in newly diagnosed patients.
- Several pilot phase II studies have evaluated the activity of bendamustine in combination with other agents in relapsed refractory MM patients.
- The activity of bendamustine in these studies varied, reflecting the heterogeneity of the patient population and previous lines of therapy.
- Other novel alkylators, such as melphalan-flufenamide and TH-302, are undergoing preclinical testing for the treatment of MM.
- The treatment of MM has seen significant advancements in recent years, particularly in the use of immunotherapy and targeted therapies.
- Proteasome inhibitors (PIs), such as bortezomib, carfilzomib, ixazomib, and oprozomib, have demonstrated clinical efficacy in MM by inhibiting the degradation of proteins and blocking the nuclear factor-kB (NF-kB) pathway.
- Carfilzomib has been approved for the treatment of MM patients who have received at least two previous therapies and are refractory to their last therapy.
- Carfilzomib has shown an overall response rate (ORR) of 52% in bortezomib-naive patients and a response rate of 20% in patients refractory to bortezomib.
- Combination therapies involving carfilzomib with lenalidomide, dexamethasone, thalidomide, cyclophosphamide, and melphalan are being explored in both relapsed/refractory and newly diagnosed MM patients.
- Oprozomib, an orally bioavailable PI, has shown clinical activity in patients with hematologic malignancies, including MM.
- Ixazomib, the first orally bioavailable PI, is being evaluated in clinical studies for the treatment of MM, with preliminary results showing low rates of significant peripheral neuropathy.
- Marizomib has shown promising results with minimal peripheral neuropathy in heavily pretreated patients.
- Monoclonal antibodies (MoAbs), such as elotuzumab and daratumumab, have demonstrated significant efficacy in MM treatment by targeting specific antigens on MM cells.
- Immunomodulatory drugs (IMIDs), including thalidomide, lenalidomide, and pomalidomide, have shown anti-MM activity by binding to cereblon and modulating the immune response.
- Combination therapies involving MoAbs, PIs, HDAC inhibitors, and IMIDs are being explored to improve outcomes for MM patients.
- The treatment of MM requires personalized medicine and targeted therapies to improve patient outcomes and minimize adverse events.
- Deacetylase inhibitors (DACis) are being investigated as a potential treatment option for MM, particularly in combination with PIs.
- Combination therapies involving DACis and PIs have shown promising results in MM treatment.
- The addition of a DACi to bortezomib may help overcome bortezomib resistance in MM patients.
- DACis have a broad spectrum of inhibition of DACs, leading to significant toxicity.
- A novel HDAC-6-specific inhibitor (rocilinostat) has been developed to overcome toxicity while maintaining efficacy.
- Agents targeting cell cycle abnormalities, such as CDK 4/6 inhibitors and kinesin spindle protein inhibitors, are being explored in MM treatment.
- Personalized medicine and the development of targeted therapies are crucial in improving outcomes for MM patients.
- The treatment of MM requires a thorough understanding of the disease's pathogenesis and the development of novel agents and combination strategies.
- The future of MM treatment looks promising, with ongoing research and positive clinical results with several agents, suggesting the potential to transform MM into a chronic disease.
Authors:
Ocio EM, Richardson PG, Rajkumar SV, Palumbo A, Mateos MV, Orlowski R, Kumar S, Usmani S, Roodman D, Niesvizky R, Einsele H, Anderson KC, Dimopoulos MA, Avet-Loiseau H, Mellqvist UH, Turesson I, Merlini G, Schots R, McCarthy P, Bergsagel L, Chim CS, Lahuerta JJ, Shah J, Reiman A, Mikhael J, Zweegman S, Lonial S, Comenzo R, Chng WJ, Moreau P, Sonneveld P, Ludwig H, Durie BG, Miguel JF
Citation:
Leukemia. 2014;28(3):525-542.
doi:10.1038/leu.2013.350